Compare
Tenaya Therapeutics, Inc. vs Inhibrx Biosciences, Inc. vs Black Diamond Therapeutics, Inc. vs Precision Biosciences Inc
| Latest fiscal year | Tenaya Therapeutics, Inc. TNYA | Inhibrx Biosciences, Inc. INBX | Black Diamond Therapeutics, Inc. BDTX | Precision Biosciences Inc DTIL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.30M | $70.00M | $34.26M |
| Revenue growth (YoY) | n/a | +550.0% | n/a | -50.1% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | 17.9% | -152.2% |
| Net margin | n/a | n/m | 32.0% | -133.4% |
| Net income | -$90.60M | -$140.06M | $22.37M | -$45.72M |
| EPS (Diluted) | -$0.59 | -$9.04 | $0.39 | -$3.56 |
| Operating cash flow | -$68.26M | -$129.79M | $29.61M | -$65.84M |
| Free cash flow | -$68.88M | -$129.82M | n/a | -$65.93M |
| Cash & equivalents | $100.55M | $124.22M | $20.99M | $110.82M |
| Total assets | $146.92M | $146.48M | $143.01M | $154.42M |
| Total liabilities | $23.66M | $138.49M | $30.80M | $62.17M |
| Shareholders' equity | $123.27M | $7.99M | $112.21M | $92.25M |
| Return on year-end equity | -73.5% | n/m | 19.9% | -49.6% |
| Shares outstanding | 216.76M | 14.58M | 57.14M | 24.09M |
Revenue, most recent five fiscal years
| Fiscal year | Tenaya Therapeutics, Inc. | Inhibrx Biosciences, Inc. | Black Diamond Therapeutics, Inc. | Precision Biosciences Inc |
|---|---|---|---|---|
| Latest | n/a | $1.30M Ended 2025-12-31 | $70.00M Ended 2025-12-31 | $34.26M Ended 2025-12-31 |
| 1 year earlier | n/a | $200.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $68.70M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.80M Ended 2023-12-31 | n/a | $48.73M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $25.10M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $115.53M Ended 2021-12-31 |